## Cohort Profile: A national prospective cohort study of SARS-CoV-2 pandemic outcomes in the U.S. -

#### The CHASING COVID Cohort Study

- 4 McKaylee M. Robertson<sup>1</sup>, Sarah Gorrell Kulkarni<sup>1</sup>, Amanda Berry<sup>1</sup>, Chloe Mirzayi<sup>1,2</sup>, Madhura
- 5 Rane<sup>1</sup>, Mindy Chang<sup>1</sup>, Shivani Kochhar<sup>1</sup>, William You<sup>1</sup>, Andrew Maroko<sup>1,3</sup>, Rebecca Zimba<sup>1</sup>,
- 6 Drew Westmoreland<sup>1</sup>, Christian Grov<sup>1,4</sup>, Angela Parcesepe<sup>1,5,6</sup>, Levi Waldron<sup>1,2</sup>, and Denis
- 7 Nash<sup>1,2</sup> for the CHASING COVID Cohort Study

#### 9 Affiliations:

2

3

8

22

25

27

30

- <sup>1</sup>Institute for Implementation Science in Population Health (ISPH), City University of New York
- 11 (CUNY); New York City, New York USA
- <sup>2</sup>Department of Epidemiology and Biostatistics, Graduate School of Public Health and Health
- Policy, City University of New York (CUNY); New York City, New York USA
- <sup>3</sup>Department of Environmental, Occupational, and Geospatial Health Sciences, Graduate
- School of Public Health and Health Policy, City University of New York (CUNY); New York
- 16 City, New York USA
- <sup>4</sup>Department of Community Health and Social Sciences, Graduate School of Public Health
- and Health Policy, City University of New York (CUNY); New York City, New York USA
- <sup>19</sup> Department of Maternal and Child Health, Gillings School of Public Health, University of
- 20 North Carolina, Chapel Hill, NC, USA
- <sup>6</sup>Carolina Population Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
- 23 WORD COUNT (ABSTRACT): 300
- 24 **WORD COUNT (BODY):** 3,994

#### 26 **CONFLICTS OF INTEREST:** None declared

- 28 **Keywords:** COVID-19; serology, seroconversion, asymptomatic infection, physical distancing;
- 29 natural history study, epidemiologic study

#### 31 **CORRESPONDING AUTHOR:**

- 32 Denis Nash, Ph.D., MPH
- 33 55 W. 125th St.
- 34 New York, NY USA 10027.
- 35 Phone: +1-(917) 740-8714
- 36 Fax: +1-866-792-7203
- 37 Email: denis.nash@sph.cuny.edu
- 38 Twitter: @epi dude

#### **ABSTRACT**

39

64 65

66

67

Purpose: The CHASING COVID Cohort study is a U.S.-based prospective cohort study launched during the upswing of the U.S. COVID-19 epidemic. The objectives are to: 1) estimate and evaluate determinants of the cumulative incidence of SARS-CoV-2 infection, disease, and deaths; 2) assess the impact of the pandemic on psychosocial and economic outcomes; and 3) assess the uptake of pandemic mitigation strategies.

Participants: We began enrolling participants March 28, 2020 using internet-based strategies. Adults ≥18 years residing anywhere in the U.S. or U.S. territories were eligible. 6,753 people are enrolled in the cohort, including participants from all 50 U.S. states, the District of Columbia, Puerto Rico, and Guam. Participants are contacted regularly to complete study assessments, including interviews and specimen collection.

Findings to date: Of 4,247 participants who provided a specimen for baseline serologic testing, 135 were seropositive by screening antibody testing (3.2%, 95% CI 2.7%-3.5%) and 90 were seropositive by confirmatory antibody testing (2.1%, 95% CI 1.7%-2.6%). Cohort data have been used to assess the role of household crowding and the presence of children in the household as potential risk factors for severe COVID-19 early in the U.S. pandemic; to describe the prevalence of anxiety symptoms and its relationship to COVID-19 outcomes and other potential stressors; and to identify preferences for SARS-CoV-2 diagnostic testing when community transmission is on the rise via a discrete choice experiment.

Future plans: The CHASING COVID Cohort Study has outlined a research agenda that involves ongoing monitoring of the cumulative incidence and determinants of SARS-CoV-2 outcomes, mental health outcomes and economic outcomes. Additional priorities include COVID-19 vaccine hesitancy, uptake and effectiveness; incidence, prevalence and correlates of long-haul COVID-19; and the extent and duration of the protective effect of SARS-CoV-2 antibodies.

#### INTRODUCTION

The Coronavirus Disease 2019 (COVID-19) pandemic has dramatically transformed life 69 across the entire United States, resulting in medical and economic challenges and threats for individuals, households and communities. The earliest research efforts have focused on 71 understanding the clinical course of COVID-19 and the most effective ways of treating people with severe symptoms or illness. As the pandemic progresses, however, we must also 73 investigate COVID-19's evolving epidemiology and the uptake/impact of non-pharmaceutical 74 interventions (NPIs)<sup>1</sup>, such as physical distancing, health messaging, and testing on the 75 cumulative incidence of SARS-CoV-2. Researchers and public health practitioners have called for cohort studies to describe the community attack rate, as well as how attack rates are 77 influenced by different approaches to NPI implementation.<sup>2</sup> There is also a need to characterize 78 both the direct and indirect effects of the SARS-CoV-2 pandemic on mental health and 79 economic outcomes. Internet-based strategies, which facilitate rapid recruitment of large and diverse samples, can be leveraged to understand and inform this swiftly changing and 81 protracted public health crisis.3,4 83 In response to the COVID-19 pandemic the CUNY Institute for Implementation Science in Population Health (ISPH) launched the prospective Communities, Households and SARS-CoV-2 Epidemiology (CHASING) COVID Cohort study on March 28, 2020. We sought to 85 prospectively recruit a geographically and socio-demographically diverse cohort of adults (18 years or older) in the United States (U.S.) and U.S. territories in order to contribute to our understanding of the spread and impact of the SARS-CoV-2 pandemic.

#### COHORT DESCRIPTION

Objectives and study design. Key objectives of the cohort study are to: 1. Estimate and 91 evaluate determinants of the cumulative incidence of SARS-CoV-2 infection, disease, and 92 deaths; and 2. Assess the pandemic's impact on psychosocial and economic outcomes (mental 93 health, unemployment, food security); and 3. Assess the uptake of pandemic mitigation 94 strategies (non-pharmaceutical interventions, testing, contact tracing, isolation/quarantine, vaccination). The study design is shown in Figure 1. Study visits (completion of questionnaires 96 online and designated by V<sub>v</sub>) are completed every 1-3 months following cohort screening and enrollment, and will continue through December 2021, for a maximum of 21 months follow-up. Initial specimen collection (S<sub>1</sub>) occurred during April-June 2020 and the second specimen (S<sub>2</sub>) will be collected in November 2020-January 2021. Additional specimen collection may occur in 100 2021, depending on epidemic activity and availability of funding. 102 Cohort eligibility. Eligibility was determined during cohort screening visits and cohort enrollment visits (Figure 2). To be eligible for inclusion in the cohort, individuals had to: 1) reside 103 in the U.S. or a U.S. territory; 2) be age 18 years or older; 3) provide valid email address; and 4) demonstrate early engagement in longitudinal study activities, including: a) completion of V<sub>1</sub> (which provided the opportunity to consent for serologic testing); and b) completion of at least one additional screening visit in addition to  $V_1$  (i.e.,  $V_0$  or  $V_2$ ) or provision of a baseline specimen for serologic testing (S<sub>1</sub>). 108 Cohort screening and enrollment. Cohort screening and enrollment began on March 28, 109 2020, at which point there were 122,000 documented COVID-19 cases and 2,200 COVID-19 deaths reported in the U.S..<sup>54</sup> Enrollment ended on August 21, 2020, when there were 783,000 111 persons diagnosed with SARS-CoV-2, including 42,000 deaths in the U.S..5 112 We used internet-based strategies that are effective for recruiting and following large and 113

114 geographically diverse online cohorts, including at-home specimen collection. 3,4,6 Persons aged

18 years and above who resided in the U.S. or U.S. territories were eligible to join the study. 115 Study participants were recruited via ads on social media platforms (e.g., Facebook, Instagram, 116 and Scruff), Qualtrics Panel, or via referral to the study (anyone with knowledge of the study 118 was allowed to invite others to participate). By relying on personal networks of participants through referrals, we aimed to bolster recruitment of persons >59 years of age, who were important to have represented in the cohort because of their risk, but may not be as active on 120 social media as younger persons. Facebook and Instagram advertisements were developed in 121 English and Spanish and were geographically targeted to people currently residing in the U.S. 122 and U.S. territories who were 18 or older. 123

Study staff systematically monitored cohort demographics and proactively adjusted advertisement strategies as needed to balance geographic and sociodemographic characteristics of respondents. For example, strategies could shift to prioritize recruitment of older persons if that demographic was poorly represented.

Interested participants were directed to a pre-enrollment survey (hosted by Qualtrics) to
be completed in their web browser on a computer or on a mobile device. A consent form
described the study, plans for follow-up assessments, and future study opportunities, including
the possibility to receive SARS-CoV-2 serologic testing as part of the study. The consent form
also described the incentive schedule: a drawing for \$100 for a pre-enrollment survey (V<sub>0</sub>) (with
with undersome survey) and gift cards ranging from \$5-30 for all participants for completion of subsequent
surveys and antibody testing.

#### 136 Study measurements

135

Measures included on the screening, enrollment and follow-up study questionnaires
were derived from previously published research (e.g., *Together 5000*<sup>3</sup>, BRFSS, and H1N1

influenza studies<sup>8,9</sup>) and from other researchers who had developed surveys for understanding
COVID-19 (e.g., Canadian Institutes of Health Research<sup>7</sup> and Food Access and Food Security
during COVID-19<sup>10</sup>). Measures were also developed *de novo* in response to the novel
pandemic. The follow-up assessments gather data on symptoms, testing, hospitalizations and
other time-varying factors (see Table 1 for key measurement realms). All study questionnaires
are available on CHASING COVID Cohort Study webpage (<a href="https://cunyisph.org/chasing-covid/">https://cunyisph.org/chasing-covid/</a>).

Daily symptom tracking. Study questionnaires are supplemented by voluntary daily symptom tracking via an innovative COVID-19 symptom tracker<sup>11</sup> that we have deployed in our cohort. The Coronavirus Pandemic Epidemiology (COPE) consortium <sup>11</sup> has developed the COVID Symptom Tracker app, which enables individuals to self-report information on COVID-19 via daily prompts for recent symptoms, health care visits, and COVID-19 testing results. The CHASING COVID Cohort Study joined the COPE consortium on April 6th, allowing our cohort members who use the app to affiliate with our cohort and consent to have their their app responses linked with the CHASING COVID Cohort Study data.

Specimen collection for serologic testing. At the V₁ assessment (end of April, 2020 through July, 2020) and the V₄ assessment (beginning November, 2020), participants were asked to self-collect a specimen at home for serologic testing. Participants are mailed dried blood spot (DBS) specimen collection kits. To facilitate self-sampling procedures, all participants are provided printed instructions and a QR code to view a video demonstrating procedures for DBS collection, and instructions to contact the study team, if they have questions. <sup>12</sup> DBS cards are returned via the U.S. Postal Service (self-addressed, stamped envelope containing EBF Foil biohazard bag<sup>™</sup>) to the study laboratory (Molecular Testing Labs). <sup>13</sup> Participants receive \$20 upon receipt of a valid specimen by the study laboratory.

Serologic testing. All DBS specimens are screened for SARS-CoV-2 antibodies using 162 the Biorad total antibody test, and specimens that are reactive are tested further using the 163 Euroimmun IgG test. Once tested, DBS specimens are banked at -80°C for future SARS-CoV-2 studies. 165 166 Data management and analysis 167 168 All data were imported and cleaned in R and SAS (V9.4). Data were geocoded based on a self-reported ZIP code. Maps were created in ArcGIS 10.7. Data from V<sub>1</sub> were used to compile 170 summary statistics on baseline characteristics. 171 172 Ethical Approval 173 The study protocol was approved by the Institutional Review Board at the City University 174 of New York (CUNY) Graduate School for Public Health and Health Policy. 175 Cohort Eligibility 176 177 Of the 10,803 individuals who completed at least one study screening or enrollment visit, 10,714 were age 18 or older, U.S. residents, and provided a valid email address for study follow-up. Of those, 7,246 completed V<sub>0</sub>, 6,829 completed V<sub>1</sub>, 5,101 completed V<sub>2</sub>, 6,482 179 consented to provide a baseline DBS specimen; 6,753 met final study eligibility criteria of completing 2 of 3 screening/enrollment visits or consenting to provide a specimen as part of V<sub>1</sub>, 181 and were considered enrolled in the cohort (Figure 2). Participants who only completed V<sub>1</sub> are routinely invited to complete additional study assessments and specimen collection. 184

#### 185 FINDINGS TO DATE

#### Cohort Characteristics

201

202

203

205

The cohort includes 6,753 participants from all 50 states, the District of Columbia, Puerto Rico and Guam (Figure 3). At V<sub>1</sub>, the median age of participants was 37 years (interquartile range: 29, 51); 73% were aged 18-49 (including 5% <21 years (N=370)), 12% were aged 50-59, and 15% were aged 60 years or older (Table 2). Just under half (45%) were male, 20% were Hispanic, 13% black non-Hispanic, 7% Asian or Pacific Islander, and 57% white non-Hispanic. A majority were currently employed (63%), 10% were retired, 13% were out of work, and 9% were students.

More than half (56%) were considered to be at increased risk for severe COVID-19
disease should they become infected with SARS-CoV-2, on the basis of age (60+), presence of
an underlying health condition (chronic lung disease, asthma [current], type 2 diabetes, serious
heart condition, kidney disease, or an immunocompromised status), or daily smoking (Table 2).
The proportion of persons with an underlying health condition increased with age category (32%
among 18-49 year olds and 65% among 60+), and the proportion of daily smokers decreased
with increasing age category (20% and 9%, respectively).

15% of participants reported being an essential worker (Table 2). By employment category, 12% were healthcare workers (half of whom reported screening or caring for COVID-19 patients), 1.5% worked in delivery services (e.g., food) and less than 1% worked in transportation (e.g., taxis). The proportion of persons employed in essential work decreased with increasing category of age.

206 NPI / Physical Distancing Behaviors Stratified by Age Categories. A high proportion of
207 participants reported avoiding large groups with >20 people in the prior two weeks and avoiding
208 handshakes or hugs (89% and 88%, respectively) (Table 3). One-quarter (25%) reported
209 working from home. A majority reported wearing gloves (58%) and masks (93%), and these

proportions significantly increased with age (57% of 18-49 year olds wore gloves versus 60% of 60+, and 92% of 18-49 year olds wore masks versus 95% of 60+, p for chi-square: <0.001 for 211 each comparison). Almost one in three (29%) participants reported stockpiling personal 213 protective equipment and 39% reported stockpiling food. The proportion of participants who reported stockpiling decreased significantly with increasing age categories (31% of 18-49 year olds stockpiled PPE versus 24% of 60+, and 42% of 18-49 year olds stockpiled food versus 215 29% of 60+, p<0.001 for each comparison). 216 217 COVID-19 symptoms and care outcomes. One in six (17% or N = 1,143) reported any COVID-like symptoms in the month prior to Visit 1 (cough, fever or shortness of breath) and this 218 decreased significantly with age (19% versus 11% among 18-49 and 60+ year olds, respectively 219 and p<0.001) (Table 3). The most common symptoms reported were new cough (10%) followed 220 221 by shortness of breath (7%) and fever (5%). Among the 17% of participants reporting COVID-like symptoms (N = 1,143), 35% (N = 396) said they called or saw a 222 physician/healthcare professional and 8% (N = 87) were hospitalized (Table 4). Compared to 223 participants at lower risk for COVID-19 illness, participants with higher risk for severe COVID-19 224 illness were more likely to report seeing a physician or hospitalization (28% versus 38% and 2% 225 versus 10%, respectively and p <0.001 for each comparison). Among all participants, 12% (N = 226 836) reported being tested for COVID-19 and 4% (N = 268) reported receiving a COVID-19 227 diagnosis. Participants at higher risk for COVID-19 illness were significantly more likely to report testing or receiving a diagnosis than participants at lower risk for severe COVID-19 illness 229 (testing: 14% versus 10% and diagnosis: 5% versus 2%, respectively and p<0.001 for each 230 comparison). 231 Baseline serologic testing, 4,247 of 6,482 consenting participants (65.5%) provided a dried 232 blood spot specimen for serologic testing, of whom 135 (3.2%, 95% CI 2.7%-3.5%) were

positive by screening and 90 (2.1%, 95% CI 1.7%-2.6%) by confirmatory serologic testing. 235 While differences were not statistically significant, seropositive persons by either test tended to be younger, male, and from the northeast U.S. Household factors and the risk of severe COVID-like illness early in the U.S. pandemic. 14 237 Early in the U.S. pandemic, crowded indoor settings and sustained close indoor contact without 238 masks were associated with an increased likelihood of SARS-CoV-2 spread. The role of such 239 exposures, as well as the role of the presence of children in the household have not been 240 investigated as risk factors for severe COVID-like illness (i.e., hospitalization). We found that the 241 risk of hospitalization due to COVID-19 was higher among participants who had (versus those 242 who did not have) children in the home, with an adjusted odds ratio [aOR] of hospitalization of 243 10.5 (95% CI 5.7-19.1) among study participants living in multi-unit dwellings and 2.2 (95% CI 244 1.2-6.5) among those living in single unit dwellings. Among participants living in multi-unit 245 246 dwellings, the aOR for COVID-19 hospitalization among participants with more than 4 persons in their household (versus 1 person) was 2.5 (95% CI 1.0-6.1), and 0.8 (95% CI 0.15-4.1) 247 among those living in single unit dwellings. This work demonstrated that, early in the U.S. 248 SARS-CoV-2 pandemic, certain household exposures likely increased the risk of both 249 250 SARS-CoV-2 acquisition and the risk of severe COVID-19 disease requiring hospitalization. 251 These findings may have implications for mask wearing and other mitigation strategies at home during the initial phase of future 'stay at home' orders. 253 The relationship between anxiety, health, and potential stressors among adults in the United States during the early phase of the COVID-19 pandemic. 15 Epidemiologic data on the mental 254 health impact of the COVID-19 pandemic in the U.S. remains limited. We found that more than 255 one-third (35%) of individuals reported moderate or severe anxiety symptoms at cohort 256 screening/enrollment visits. Having lost income due to COVID-19 (adjusted prevalence ratio 257

[aPR] 1.27 (95% Confidence Interval [CI] 1.16, 1.30), having recent COVID-like symptoms (aPR 1.17 (95% CI 1.05, 1,31), and having been previously diagnosed with depression (aPR 1.49, 259 (95% CI 1.35, 1.64) were positively associated with moderate or severe anxiety symptoms. This 260 261 work demonstrated that anxiety symptoms were common and appear to be elevated among adults in the U.S. during the early phase of the COVID-19 pandemic. Strategies to screen and 262 treat individuals at increased risk of anxiety, such as individuals experiencing financial hardship 263 and individuals with prior diagnoses of depression, should be developed and implemented. 264 SARS-CoV-2 Testing Service Preferences of Adults in the United States: Discrete Choice 265 Experiment<sup>16</sup> and Patterns of SARS-CoV-2 testing preferences in a national cohort in the United States.<sup>17</sup> A discrete choice experiment (DCE) was used to assess the relative importance of 267 type of SARS-CoV-2 test, specimen type, testing venue, and results turnaround time. 268 Turnaround time for test results had the highest relative importance (30.4%), followed by test 269 type (28.3%), specimen type (26.2%), and venue (15.0%). Participants preferred fast results on 270 both past and current infection and using a noninvasive specimen, preferably collected at home. 271 Simulations suggested that providing immediate or same day test results, providing both PCR 272 and serology, or collecting oral specimens would substantially increase testing uptake over the 273 current typical testing option. Using latent class analysis, we also found five distinct patterns in testing preferences in the cohort, including groups of 'comprehensive testers', 'fast-track testers', 'dual testers', 'non-invasive, dual testers', and 'home testers'. 17 We concluded that testing strategies that offer account for preferences and their heterogeneity would likely have the most uptake and engagement among residents in communities with increasing community transmission of SARS-CoV-2. 279

#### 281 Future plans

The CHASING COVID Cohort Study will continue to conduct ongoing monitoring of the 283 cumulative incidence and determinants of SARS-CoV-2 outcomes (including mortality), mental health outcomes (e.g., anxiety and depression) and economic outcomes (e.g., income loss, food security), as well as overall and cause-specific mortality. A number of longitudinal analyses are ongoing or planned using the data that have already been collected, with priorities including 286 those related to COVID-19 vaccine hesitancy, uptake and effectiveness; NPI engagement before and after vaccination; incidence, prevalence and correlates of long-haul COVID-19; 288 extent and duration of protective effect of SARS-CoV-2 antibodies.

#### DISCUSSION 291

282

284

285

287

289

290

292

293

294

296

297

298

299

300

This longitudinal cohort study enrolled 6,753 persons from all 50 U.S. states, the District of Columbia, Puerto Rico and Guam, and was rapidly established during the upswing of the SARS-CoV-2 pandemic in the U.S. The cohort is geographically and socio-demographically diverse, and includes participants from many active hotspots, as well as health care workers and other essential workers, and individuals who are vulnerable to severe outcomes associated with SARS-CoV-2 infection. Initial serologic testing indicates that the cohort overwhelmingly had no evidence of prior SARS-CoV-2 infection at the time of specimen collection, suggesting a high potential for observing subsequent seroconversions, and the extent of protective effects of new vaccines.

At cohort screening/enrollment, nearly one in six participants (17%) reported having had 301 recent COVID-like symptoms. However, only small proportions of participants reported having been tested for or diagnosed with SARS-CoV-2 (12% and 4%, respectively). Participants with 303 elevated risk for COVID-19 illness were more likely to report seeking care, hospitalization, and 304 305 testing than participants without elevated risk. This is consistent with both the recommendations for testing and care seeking during the late spring and early summer of 2020, as well as the relative lack of SARS-CoV-2 testing availability in most parts of the U.S.

Recent evidence of waning of SARS-CoV-2 antibodies to both nucleocapsid and spike 308 309 proteins, combined with the timing of specimen collection for many participants in our cohort, make our serology-based proxy measure for the cumulative incidence of SARS-CoV-2 infection challenging to interpret. 18 Since SARS-CoV-2 antibodies may wane with time, and waning may 311 be faster for antibodies to the nucleocapsid protein of the SARS-CoV-2 virus<sup>19</sup>, we have likely underestimated the cumulative incidence of infection in the cohort leading up to enrollment. 313 Subsequent antibody testing in our cohort (S<sub>2</sub>) will help clarify whether participants who were positive on the screening test for total SARS-CoV-2 antibodies and negative on the follow-up 315 IgG test represent early infections or false positives. However, antibody waning may also make this interpretation challenging, as up to 5 months may have passed between the first and 317 second specimen collection for some participants. Recently, other teams have developed algorithms to correct seroprevalence estimates for waning<sup>20</sup>, and we may be able to use these 319 approaches to correct our estimates of cumulative incidence in our cohort going forward. 320 Limitations of serological assays notwithstanding<sup>21</sup>, recent cross-sectional serosurveys done 321 322 prior to the relaxing of physical distancing have reported cumulative incidence estimates ranging from 1.7% in Indiana to 21% in New York City, and <10% nationally as of the end of September 2020.18,22-26

Strengths of our cohort study include its prospective design, allowing direct observation of seroconversions and incident COVID-19 disease among those who were unexposed and/or disease free at enrollment. We also have been able to include a range of relevant measures, for a more comprehensive view of the impact of the pandemic and its response on several outcomes in addition to SARS-CoV-2 infection, including mental health and economic

outcomes, vaccine uptake, and long-haul COVID. The longitudinal design also allows prospective estimation of the incidence of COVID-19 disease among those with antibodies to SARS-CoV-2, allowing assessment of the extent to which SARS-CoV-2 antibodies, acquired through natural infection or through vaccination, offer short-term protection against subsequent disease. Prospective studies are complementary to, and offer some strengths over, cross 334 sectional studies, especially in the context of rapidly evolving emergencies and the associated 335 public health response. While repeat cross-sectional surveys are valuable in a pandemic, 336 including their ability to assess trends in many important outcomes, they cannot assess what 337 factors may influence change over time in an individual's or a household's exposures and 338 339 outcomes.

Our study includes those who recover from SARS-CoV-2 infection (asymptomatic or mild) and COVID-19 disease, and follows these individuals over time to characterize their recovery, including persistence of symptoms, onset and persistence of new symptoms, and persistence of antibodies. This will allow us to characterize of the epidemiology of long-haul COVID (aka post-acute covid syndrome or PACS).<sup>27</sup> We will also be able to assess mortality and related risk factors via matching with the US National Death Index.<sup>28</sup>

Our approach employs protocols for overcoming common pitfalls of fully online studies (e.g., repeat/duplicate participation). Our online, volunteer recruitment approach allows us to sample individuals who may not be reached by traditional telephone recruitment approaches, which can have very low response rates. As part of our enrollment procedures, we record IP address, email addresses, participant contact information, and require participants to have valid U.S. mailing addresses (required for those who opt to receive an at-home SARS-CoV-2 specimen collection kit). Participants are "known" to the research team (name, email, address), thus averting some of the traditional shortcomings of online-only studies (particularly

4 anonymous, cross-sectional online studies).

Our cohort study has limitations worth noting, as they inform what can and cannot be 355 assessed. First, while our study is national in scope, we will be unable to provide estimates of seroprevalence and cumulative incidence that are representative of that of the U.S. population. 357 Second, we will likely underestimate the incidence of COVID-19 related hospitalizations. Most research studies deployed in the middle of a pandemic, including ours, will by definition, 359 produce some biased estimates since they will not include some information on participants who 360 died from COVID-19, were hospitalized with COVID-19 after recruitment and were either lost to 361 follow-up or were too sick to participate in the research activities. We will ascertain deaths in our 362 participants using the National Death Index. Additionally, from published studies, we will 363 routinely assess bias in our estimates due to these factors and adjust them accordingly when 364 possible. Third, we will largely be unable to conduct state or county specific analyses, except for 365 a few localities with high participation (e.g., New York, Texas, Florida and California). Finally, although our sample is not representative of the entire U.S. population, it is geographically 367 representative and socio-demographically diverse. Our study will complement other efforts and 368 approaches to address similar research questions, such as the NIH's national study<sup>29</sup>, and the 369 COVID-Vu study.30 Indeed, it will be important to assess the extent to which the different strategies used in each of these cohort studies reach similar or divergent conclusions.

#### Collaboration, data sharing, and dissemination of findings

372

We will post a deidentified, HIPAA compliant, public use version of Visit 1 and follow-up
data on GitHub.<sup>31</sup> Data will be presented as flat text files (CSV) formatted for compatibility with
county-level longitudinal case load datasets, including date, county, state, and fips code. We will

continue to provide direct feedback to our cohort and other stakeholders who have signed up for updates via follow-up emails to participants, and the CUNY ISPH study website.<sup>32</sup>

#### Conclusion

379

380

381 A geographically and socio-demographically diverse group of participants, largely without serologic evidence of prior SARS-CoV-2 infection, was rapidly enrolled into a national 382 longitudinal cohort study during the upswing of the SARS-CoV-2 pandemic in the U.S. Strengths 383 of the study include the potential for direct observation of seroconversions and incident 384 COVID-19 disease in areas of active transmission, and related determinants. The study is also 385 examining a range of other outcomes, including psychosocial and employment outcomes, and 386 long-haul COVID. The study has the potential to monitor and assess the uptake and impact of 387 the public health response to control and mitigate the SARS-CoV-2 pandemic in the U.S., 388 389 including the uptake of recently authorized vaccines.

#### Contributors

390

396

397

MMR, SGK, CG and DN conceptualized the study. SK, MC and MMR performed statistical analyses. MR and DN wrote the first draft of the paper. MMR, SGK, AB, CM, SK, MR, WY, AM, RZ, DW, CG, AP, LW, and DN contributed to interpreting the data and to the writing and revising of the manuscript.

#### Acknowledgements

The authors wish to thank the participants of the CHASING COVID Cohort Study. We are grateful to you for your contributions to the advancement of science around the SARS-CoV-2 pandemic.

Funding
Funding for this project is provided by The National Institute for Allergies and Infectious
Diseases (NIAID), award number 3UH3Al133675-04S1 (MPIs: D Nash and C Grov), the
CUNY Institute for Implementation Science in Population Health (cunyisph.org) and the
COVID-19 Grant Program of the CUNY Graduate School of Public Health and Health Policy,
and NICHD grant P2C HD050924 (Carolina Population Center).

#### 410 Table 1: Realms of Measurement in the CHASING COVID Cohort

411

	Measure	Cohort screening (V0)	Cohort enrollment (V1)	Follow-up (V2)	Follow-up (V3)	Parents
Individual and household characteristics	Sociodemographics (various measures)	✓	✓	✓		✓
	Household size and age distribution	✓				✓
	Educational/childcare experience of household children				✓	~
	Height and weight			✓		
	Employment status	✓	✓	✓	✓	✓
	Food and housing security		✓	✓		
2	Pre-existing/co-morbid conditions	✓				
윭	Smoking and vaping behaviors	✓				~
*	Essential employee status*	✓	✓	✓	✓	
9	NPI uptake and other precautions	✓	✓	✓	✓	
-	Influence of social media on COVID knowledge and beliefs	✓	✓			
COVID-19 risk factors	Understanding of epidemiological concepts (antibodies, herd immunity)				✓	
Health care- related	Health care access and insurance status	✓	✓	✓	✓	
Health care- related	Sexual and reproductive health				✓	
9	Recent COVID-like symptoms	✓	✓	✓	✓	
COVID-19-related outcomes	Medical care for COVID-like symptoms	✓	✓	✓	✓	
ID-19-rek outcomes	Recent SARS/COV2 testing** and diagnosis	✓	✓	✓	✓	
otoc	Contact tracing***, quarantine, and isolation			~	✓	
ĕ°	Serology (SARS/COV2 IgM and IgG)		✓			
0	Vaccine uptake			✓	✓	
	Anxiety (GAD-7) and risk perceptions	✓	✓	✓	✓	✓
善	Depression (PHQ8)		✓	~		~
Mental and physical health	PTSD (PC-PTSD-5)					✓
	Resilience, stress, and coping					✓
	Social support		✓	✓	✓	✓
and	IPV		✓	✓	✓	
/ental	Drug use		✓			✓
	Alcohol use (AUDIT)		✓			✓
	Physical Activity				<b>V</b>	

<sup>\*</sup>front-line health care workers, hospital staff, first responders, grocery clerks, delivery workers, educators (V3 only)

<sup>\*\*</sup> V3 covers testing experience and expanded testing questions

<sup>\*\*\*</sup> V3 covers informal contact tracing as well as onward transmission

#### 413 TABLE 2: Characteristics of CHASING COVID Cohort

		Total		18-49		50-59	60+		Chi- square
	N	%	N	%	N	%	N	%	p-value
Total	6,753	100	4,931	100	797	100	1,025	100	
Age (Median, IQR)	37 (2	29, 51)	33 (2	27, 39)	54 (5	51, 57)	66 (63, 71)		
Gender				<0.0001					
Male	3,070	45	2,274	46	374	47	422	41	
Female	3,516	52	2,503	51	413	52	600	59	
Transgender/Non-Binary	167	2	154	3	10	1	3	0	
Race/Ethnicity									<0.0001
Hispanic	1,326	20	1,152	23	102	13	72	7	
Black NH	911	13	764	15	92	12	55	5	
Asian/Pacific Islander	462	7	420	9	20	3	22	2	
White NH	3,837	57	2,431	49	558	70	848	83	
Other	217	3	164	3	25	3	28	3	
Employment									<0.0001
Employed	4,254	63	3,389	69	527	66	338	33	
Out of work	869	13	676	14	128	16	65	6	
Homemaker	355	5	280	6	51	6	24	2	
Student	574	9	562	11	10	1	2	0	
Retired	698	10	21	0	81	10	596	58	
Missing	3	0	3	0	0	0	0	0	
Income									<0.0001
<\$50,000	2,715	40	2,083	42	276	35	356	35	
\$50,000 to \$99,999	2,034	30	1,467	30	234	29	333	32	
\$100,000+	1,803	27	1,216	25	276	35	311	30	
Missing	201	3	165	3	11	1	25	2	
Region									0.0154
Midwest	1,135	17	813	16	136	17	186	18	
Northeast	1,896	28	1,347	27	251	31	298	29	
South	2,072	31	1,552	31	229	29	291	28	
West	1,642	24	1,216	25	180	23	246	24	
US Dependent	8	0	3	0	1	0	4	0	
Urban area	2,904	43	2,233	45	318	40	353	34	<0.0001
High Risk for Severe COVID-191	3,764	56	2,271	46	468	59	1,025	100	<0.0001
Any Underlying Health Condition <sup>2</sup>	2,637	39	1,557	32	412	52	668	65	<0.0001
Smoker <sup>3</sup>	1,203	18	985	20	121	15	97	9	<0.0001
Essential Worker	1,021	15	862	17	101	13	58	6	<0.0001
All Healthcare Workers (HCW)	809	12	690	14	73	9	46	4	<0.0001
HCW Who Screen or Care for COVID-19 Patients	403	6	357	7	32	4	14	1	<0.0001
Law Enforcement	33	0	23	0	8	1	2	0	0.0047
Emergency Response	23	0	19	0	3	0	1	0	0.3492
Delivery (e.g. food)	101	2	96	2	3	0	2	0	<0.0001
Transportation (e.g. taxi or airline)	55	1	34	1	14	2	7	1	0.0070

<sup>1.</sup> High risk for severe illness included people 60 years or older or reporting any underlying health condition, daily smoking or screening or providing care for COVID-19 patients

<sup>2.</sup> Any underlying health condition includes people who reported chronic lung disease, asthma (current), type 2 diabetes, serious heart condition (history of MI, angina, or CHD), kidney disease, HIV or immunocompromised

<sup>3.</sup> People who report they smoke cigarettes or e-cigarettes daily

## 415 Table 3: Behaviors and Symptoms by Age Category of CHASING COVID Cohort


		Total		18-49		50-59		60+	Chi- Square
	N	%	Ν	%	Ν	%	N	%	P-value
Total	6,753	100	4,931	100	797	100	1,025	100	
Behaviors in the past month									
Avoided Groups >20	6,025	89	4,337	88	734	92.1	954	93	<0.0001
Avoided Handshakes	5,969	88	4,272	87	746	93.6	951	93	<0.0001
Bought Firearm	382	6	357	7	15	1.88	10	1	<0.0001
Worked from Home	1,673	25	1,413	29	158	19.82	102	10	<0.0001
Wore Gloves	3,920	58	2,831	57	474	59.47	615	60	0.2137
Wore Mask	6,250	93	4,520	92	753	94.48	977	95	<0.0001
Stockpiled PPE	1,948	29	1,536	31	169	21.2	243	24	<0.0001
Stockpiled Food	2,659	39	2,089	42	268	33.63	302	29	<0.0001
Quarantined	4,282	63	3,237	66	449	56.34	596	58	<0.0001
Symptoms since last survey/in past	Symptoms since last survey/in past month								
Covid-like symptoms (cough, fever, or shortness of breath)	1,143	17	918	19	117	14.68	108	11	<0.0001
New Cough	664	10	553	11	57	7.15	54	5	<0.0001
Fever	312	5	260	5	33	4.14	19	2	<0.0001
Shortness Breath	488	7	376	8	52	6.52	60	6	0.0984
Coughing Blood	52	1	50	1			2	0	0.0007

## 418 Table 4: CHASING COVID Cohort Care Outcomes Stratified by Risk for Severe COVID-19

### 419 Illness


	Overall		No		Yes		
Variable	N	%	N	%	N	%	Chi- Square p-value
All with COVID-like symptoms: cough, fever, or shortness of breath	1,143	100	366	32	777	68	
Saw Physician							0.0042
Yes	396	35	102	28	294	38	
No	741	65	262	72	479	62	
Missing	6	1	2	1	4	1	
Hospitalized							<0.0001
Yes	87	8	7	2	80	10	
No	1,054	92	358	98	696	90	
Missing	2	0	1	0	1	0	
All Participants	6,753	100	2,989	100	3,764	100	
Tested							<0.0001
Yes	836	12	291	10	545	14	
No, but tried to be tested	743	11	290	10	453	12	
No, did not need to be tested	5,134	76	2,389	80	2,745	73	
Missing	40	1	19	1	21	1	
COVID-19 Diagnosis							<0.0001
Yes	268	4	68	2	200	5	
No	605	9	238	8	367	10	
Don't know	26	0	12	0	14	0	
Missing	5,854	87	2,671	89	3,183	85	

## 421 Figure 1: Design for the CHASING COVID Cohort Study




### 423 Figure 2. Enrollment and follow-up in the CHASING COVID Cohort

#### **CHASING COVID Cohort**



# Figure 3. Geographic distribution of CHASING COVID Cohort participants by county of residence, N = 6,753



#### 430 REFERENCES

- Hutchins HJ, Wolff B, Leeb R, et al. COVID-19 Mitigation Behaviors by Age Group United 431 States, April-June 2020. MMWR Morb Mortal Wkly Rep 2020;69(43):1584-90. 432
- 433 **2**. Lipsitch M, Swerdlow DL, Finelli L. Defining the epidemiology of Covid-19—studies needed. N Engl J Med 2020;382(13):1194-6. 434
- 435 3. Grov C, Westmoreland DA, Carneiro PB, et al. Recruiting vulnerable populations to participate in HIV prevention research: findings from the Together 5000 cohort study 436
- [Internet]. Annals of Epidemiology. 2019;35:4–11. Available from: 437
- http://dx.doi.org/10.1016/j.annepidem.2019.05.003 438
- 439 4. Nash D, Stief M, MacCrate C, et al. A Web-Based Study of HIV Prevention in the Era of Pre-Exposure Prophylaxis Among Vulnerable HIV-Negative Gay and Bisexual Men, 440
- Transmen, and Transwomen Who Have Sex With Men: Protocol for an Observational 441
- Cohort Study [Internet]. JMIR Research Protocols. 2019;8(9):e13715. Available from: 442
- http://dx.doi.org/10.2196/13715 443
- 444 5. COVID-19 United States Cases by County [Internet]. Johns Hopkins Coronavirus Resource Center. [cited 2020 Apr 23]; Available from: https://coronavirus.jhu.edu/us-map 445
- Grov C, Westmoreland D, Rendina J, Nash D. Seeing is believing? Unique capabilities of 446 6. internet-only studies as a tool for implementation research on HIV prevention for men who 447 have sex with men: A review of studies and methodological considerations. JAIDS 2019;In 448 press. 449
- Qualtrics XM Experience Management Software [Internet]. Qualtrics. 2015 [cited 2020 Apr 450 7. 26]; Available from: https://www.gualtrics.com/ 451
- 452 8. Santibanez TA, Singleton JA, Santibanez SS, Wortley P, Bell BP. Socio-demographic differences in opinions about 2009 pandemic influenza A (H1N1) and seasonal influenza 453 vaccination and disease among adults during the 2009--2010 influenza season. Influenza 454 Other Respi Viruses 2013;7(3):383-92. 455
- Kumar S, Quinn SC, Kim KH, Daniel LH, Freimuth VS. The impact of workplace policies 456 9. and other social factors on self-reported influenza-like illness incidence during the 2009 457 H1N1 pandemic. Am J Public Health 2012;102(1):134–40. 458
- 459 10. Niles MT, Neff R, Biehl E, Bertmann F, Morgan EH, Wentworth T. Food Access and Security During Coronavirus Survey- Version 1.0 [Internet]. 2020; Available from: 460
- https://doi.org/10.7910/DVN/RQ6NMG 461
- 462 11. Drew DA, Nguyen LH, Steves CJ, et al. Rapid implementation of mobile technology for real-time epidemiology of COVID-19. medRxiv 2020;2020.04.02.20051334. 463
- 464 12. How To Collect Blood with Dry Blood Spot Kit Molecular Testing Labs [Internet]. Molecular Testing Labs. [cited 2020 Apr 13]; Available from: 465

- 466 https://moleculartestinglabs.com/how-to-collect/
- Home Molecular Testing Labs [Internet]. Molecular Testing Labs. [cited 2020 Apr
   26]; Available from: https://moleculartestinglabs.com/
- 14. Nash D, Qasmieh S, Robertson M, et al. Household factors and the risk of severe
   COVID-like illness early in the US pandemic. medRxiv [Internet] 2020; Available from:
   http://dx.doi.org/10.1101/2020.12.03.20243683
- 15. Parcesepe AM, Robertson M, Berry A, et al. The relationship between anxiety, health, and potential stressors among adults in the United States during the COVID-19 pandemic. medRxiv [Internet] 2020;Available from: http://dx.doi.org/10.1101/2020.10.30.20221440
- 475
   16. Zimba R, Kulkarni S, Berry A, et al. SARS-CoV-2 Testing Service Preferences of Adults in
   476 the United States: Discrete Choice Experiment. JMIR Public Health Surveill
   477 2020;6(4):e25546.
- 17. Romo ML, Zimba R, Kulkarni S, et al. Patterns of SARS-CoV-2 testing preferences in a
   national cohort in the United States. medRxiv [Internet] 2020; Available from:
   https://www.medrxiv.org/content/10.1101/2020.12.22.20248747v1.abstract
- 18. Bajema KL, Wiegand RE, Cuffe K, et al. Estimated SARS-CoV-2 Seroprevalence in the US
   as of September 2020. JAMA Intern Med [Internet] 2020; Available from:
   http://dx.doi.org/10.1001/jamainternmed.2020.7976
- 484 19. Murrell I, Forde D, Tyson L, et al. A longitudinal comparison of spike and nucleocapsid 485 SARS-CoV-2 antibody responses in a tertiary hospital's laboratory workers with validation 486 of DBS specimen analysis. medRxiv 2020;2020.10.29.20219931.
- 20. Shioda K, Lau MS, Kraay AN, et al. Estimating the cumulative incidence of SARS-CoV-2 infection and the infection fatality ratio in light of waning antibodies. medRxiv [Internet] 2020;Available from: http://dx.doi.org/10.1101/2020.11.13.20231266
- 490 21. Milani GP, Dioni L, Favero C, et al. Serological follow-up of SARS-CoV-2 asymptomatic subjects. Sci Rep 2020;10(1):20048.
- 22. Cuomo Says 21% of Those Tested in N.Y.C. Had Virus Antibodies [Internet]. New York Times. 2020 [cited 2020 Apr 25]; Available from:
- https://www.nytimes.com/2020/04/23/nyregion/coronavirus-new-york-update.html
- 23. Bendavid E, Mulaney B, Sood N, et al. COVID-19 Antibody Seroprevalence in Santa Clara
   County, California. medRxiv [Internet] 2020;Available from:
   https://www.medrxiv.org/content/10.1101/2020.04.14.20062463v1.abstract
- 498 24. USC-LA County Study: Early Results of Antibody Testing Suggest Number of COVID-19
   499 Infections Far Exceeds Number of Confirmed Cases in Los Angeles County [Internet]. [cited
   500 2020 Apr 25]; Available from:
- http://publichealth.lacounty.gov/phcommon/public/media/mediapubhpdetail.cfm?prid=2328
- 502 25. Menachemi N, Yiannoutsos CT, Dixon BE, et al. Population Point Prevalence of

SARS-CoV-2 Infection Based on a Statewide Random Sample - Indiana, April 25-29, 2020.

504 MMWR Morb Mortal Wkly Rep 2020;69(29):960–4.

- 505 26. Biggs HM, Harris JB, Breakwell L, et al. Estimated Community Seroprevalence of
- SARS-CoV-2 Antibodies Two Georgia Counties, April 28-May 3, 2020. MMWR Morb
- 507 Mortal Wkly Rep 2020;69(29):965–70.
- 508 27. Davis HE, Assaf GS, McCorkell L, et al. Characterizing Long COVID in an international
- cohort: 7 months of symptoms and their impact [Internet]. bioRxiv. 2020; Available from:
- 510 http://medrxiv.org/lookup/doi/10.1101/2020.12.24.20248802
- 511 28. Wentworth DN, Neaton JD, Rasmussen WL. An evaluation of the Social Security
- Administration master beneficiary record file and the National Death Index in the
- ascertainment of vital status. Am J Public Health 1983;73(11):1270–4.
- 514 29. NIH Begins Study to Quantify Undetected Cases of Coronavirus Infection | NIH: National
- Institute of Allergy and Infectious Diseases [Internet]. [cited 2020 Apr 12]; Available from:
- 516 https://www.niaid.nih.gov/news-events/nih-begins-study-quantify-undetected-cases-coronav
- 517 irus-infection
- 518 30. Emory launches national COVID-19 home testing study to estimate infection and antibody
- rates in the U.S [Internet]. [cited 2020 Nov 30]; Available from:
- https://sph.emory.edu/news/news-release/2020/06/covid-vu-study.html
- 521 31. Where the world builds software [Internet]. Github; [cited 2021 Jan 4]. Available from:
- 522 https://github.com/

- 523 32. CHASING COVID Study Updates | CUNY ISPH [Internet]. CUNY ISPH. [cited 2020 Apr
- 524 25]; Available from: https://cunyisph.org/chasing-covid-study-updates/